Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

Epigenetic changes can lead to development of GISTs, other cancers

Epigenetic changes can lead to development of GISTs, other cancers

Drug combinations could become first-line treatment for metastatic kidney cancer

Drug combinations could become first-line treatment for metastatic kidney cancer

Physicians more likely to prescribe drugs of manufacturers who paid them money

Physicians more likely to prescribe drugs of manufacturers who paid them money

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Exelixis presents CABOSUN and METEOR trial results in patients with advanced renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

FDA approves combination immunotherapy for treatment of kidney cancer

FDA approves combination immunotherapy for treatment of kidney cancer

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Immunotherapy combination increases overall survival in people with kidney cancer, study shows

Oncolytic virus alerts the immune system to attack tumors

Oncolytic virus alerts the immune system to attack tumors

New organ-on-a-chip technology provides simple setting to study blood vessel formation

New organ-on-a-chip technology provides simple setting to study blood vessel formation

Novel drug shows promise in treating metastatic kidney cancer

Novel drug shows promise in treating metastatic kidney cancer

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Combination immunotherapy shows better overall survival in kidney cancer patients

Combination immunotherapy shows better overall survival in kidney cancer patients